Why are patients with severe or end-stage kidney disease monitored for metabolic acidosis during treatment with lumasiran sodium (Oxlumo)?

Lumasiran sodium (Oxlumo) increases plasma glycolate levels, which may increase the risk of metabolic acidosis or worsen pre-existing metabolic acidosis in patients with severe or end-stage kidney disease, so these patients are monitored for signs and symptoms.